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7LETTER TO THE EDITOR
e: High Rate of Graft Failure in 25 Patients with
hronic Myelogenous Leukemia Conditioned with a
educed-Intensity Regimen of 550 cGy Total Body
rradiation and Cyclophosphamide for Unrelated
onor Transplantation
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cHistorically, myeloablative conditioning regimens
or patients with chronic myelogenous leukemia
CML) undergoing unrelated donor (URD) hemato-
oietic stem cell transplantation (HSCT) have incor-
orated high-dose (1000 cGy) total body irradiation
TBI) and chemotherapy [1,2]. These regimens are
ssociated with a high risk of transplant-related mor-
ality (TRM). Recent clinical trials have explored re-
uced-intensity conditioning (RIC) regimens in an
ffort to reduce TRM.
Previously, we investigated an RIC regimen con-
isting of single-exposure, low-dose (550 cGy), high-
ose-rate (30 cGy/min) TBI and cyclophosphamide
or HLA-matched sibling peripheral blood stem cell
PBSC) transplantation as therapy for patients with
ML in chronic phase (CP) [3]. Graft-versus-host
isease prophylaxis consisted of cyclosporine alone.
e observed no graft failure and relatively low rates
f relapse (10%) and TRM (17%). At day 30, 93%
f patients had 100% donor chimerism in unsorted
arrow cells. The overall survival at 2 years was 83%.
n the basis of these results, we hypothesized that this
egimen would be effective for patients with CML
ndergoing URDHSCT. Between 1997 and 2003, 25
onsecutive patients with CML undergoing URD
SCT were conditioned with this regimen. Disease
tatus at transplantation was CP, accelerated phase,
nd blast phase in 10, 6, and 9 patients, respectively.
ources of stem cells included non–T cell–depleted
one marrow (n  23) and PBSC (n  2). Graft-
ersus-host disease prophylaxis consisted of cyclospor-
ne, methotrexate, and corticosteroids. The median
atient age was 39 years (range, 21-55 years). Time
rom diagnosis to transplantation was 24 months
range, 6-113 months). Donor/recipient pairs were
LA-A, -B, and -DRB1 matched in 22 and single-
ntigen mismatched in 3. Donor/recipient pairs were
LA-A, -B, -C, -DRB1, and -DQB1 matched in 1768%). The median administered cell numbers were w
26.78 (range, 0.24-15.6)  108 total nucleated cells per
ilogram and 3.22 (range, 1.08-15.9)  106 CD34
ells per kilogram. Eighteen patients received -inter-
eron before HSCT; this was discontinued 3 or more
onths before transplantation in 14. The median fol-
ow-up of the 4 surviving patients was 925 days (range,
66-1703 days).
Graft failure, as previously deﬁned [3], occurred in
(3 primary and 2 secondary) of 22 evaluable patients
23%). Graft failure occurred in 4 patients in CP and
in accelerated phase. Three patients were not evalu-
ble for engraftment because of early TRM (n  1)
nd persistent cytogenetic disease (n 2). At day30,
he number of patients with 100%, 50% to 99%, and
% to 49% donor chimerism in unseparated marrow
ucleated cells by variable numbers of tandem repeat
VNTR) was 15 (68%), 4 (18%), and 3 (14%), respec-
ively. The rate of graft failure in patients with CML
23%) was higher than the rate (3%) that we observed
n patients with other diagnoses undergoing URD
SCT with the same RIC regimen (P  .004) [4].
dditionally, the incidence of 100% donor chimerism
n unseparated marrow cells at day 30 for patients
ith CML was lower than that observed for patients
ith acute leukemia in remission (68% versus 96%,
espectively; P  .015) [5].
After graft failure, therapy included withdrawal of
mmunosuppression (n  5), institution of imatinib
esylate with or without additional chemotherapeutic
gents (n 4), or a second URDHSCT (n 3). After
herapy, 4 patients achieved a partial or complete
ematologic response, and 1 patient also achieved a
omplete cytogenetic response. However, no patient
emonstrated evidence of donor cell recovery (1%
onor cells by VNTR) at any subsequent follow-up.
High rates of graft failure have been reported for
atients with CML undergoing URD HSCT after
onditioning with other regimens. In 1423 patients
ith CML undergoing URD HSCT after conven-
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Graft Failure in 25 Patients with Chronic Myelogenous Leukemia
Bional TBI-based regimens, the graft failure rate was
5.5% [1]. With reﬁnements in HLA typing method-
logy, the rate of graft failure has been lower in more
ecent reports [2]. The risk of graft failure in patients
ith CML has also been high after nonmyeloablative
egimens for URD HSCT. A RIC regimen of 200
Gy of TBI and ﬂudarabine was associated with a graft
ailure rate of 29% (4 of 14 patients) [6]. A non–TBI-
ased RIC regimen of ﬂudarabine, busulfan, and an-
ithymocyte globulin was associated with a graft fail-
re rate of 44% (3 of 8 patients) [7]. Thus, the rate of
raft failure in patients with CML undergoing URD
SCT remains disturbingly high, especially with cur-
ent RIC regimens.
In patients with CML undergoing URD HSCT
ith RIC regimens, assessment of graft failure must be
ade cautiously, because early donor cell chimerism
ay be present but at undetectable levels with stan-
ard VNTR techniques. Subsequently, the percentage
f donor cells may increase either spontaneously or in
esponse to the addition of other therapies (imatinib
esylate, discontinuation of immunosuppression, and
o on) [8]. However, we did not observe this phenom-
non in the 5 patients in this study who experienced
raft failure.
In an effort to reduce the risk of graft failure in
atients with CML undergoing URD HSCT, we are
xamining 2 modiﬁcations to this single-exposure,
ow-dose (550 cGy) TBI-based regimen. Alemtu-
umab has been added to further immunosuppress the
ecipient. Alemtuzumab is administered 3 weeks be-
ore transplantation such that the serum antibody con-
entration at the time of stem cell infusion is relatively
ow, thus minimizing posttransplantation drug inter-
ctions with donor T cells mediating graft-versus-
eukemia effects [9]. Additionally, PBSCs are being
sed (instead of bone marrow) on the basis of obser-
ations from Maris et al. [6] that the use of PBSCs
versus bone marrow) was associated with a signiﬁ-
antly lower risk for graft failure in patients condi-
ioned with 200 cGy of TBI and ﬂudarabine. Alterna-
ive means of recipient immunosuppression or donor
eukocyte infusions could be used to reduce the risks
f graft failure and mixed chimerism in these patients. S
B&MTEFERENCES
. McGlave PB, Shu X-O, Wen W, et al. Unrelated donor marrow
transplantation for chronic myelogenous leukemia: 9 years’ ex-
perience of the National Marrow Donor Program. Blood. 2000;
95:2219-2225.
. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow trans-
plants from unrelated donors for patients with chronic myeloid
leukemia. N Engl J Med. 1998;338:962-968.
. Khoury H, Adkins D, Brown R, et al. Low incidence of trans-
plant-related complications in patients with chronic myeloid
leukemia undergoing allogeneic stem cell transplantation with
low dose (550 cGy) total body irradiation conditioning regimen.
Biol Blood Marrow Transplant. 2001;7:352-358.
. Girgis M, Hallemeier C, Blum W, et al. Chimerism and clinical
outcomes of 110 unrelated donor bone marrow transplant recip-
ients conditioned with low dose (550 cGy), single exposure total
body irradiation and cyclophosphamide. Blood. In press.
. Hallemeier C, Girgis M, BlumW, et al. Outcomes of adults with
acute myelogenous leukemia in remission given 550 cGy single
exposure total body irradiation, cyclophosphamide, and unre-
lated donor bone marrow transplantation. Biol Blood Marrow
Transplant 2004;10:310-319.
. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched
unrelated donor hematopoietic cell transplantation after nonmy-
eloablative conditioning for patients with hematologic malignan-
cies. Blood 2003;102:2021-2030.
. Bornhäuser M, Thiede C, Platzbecker U, et al. Dose-reduced
conditioning and allogeneic hematopoietic stem cell transplan-
tation from unrelated donors in 42 patients. Clin Cancer Res
2001;7:2254-2262.
. De Angelo DJ, Hochberg EP, Alyea EP, et al. Extended fol-
low-up of patients treated with imatinib mesylate (Gleevec) for
CML relapse following allogeneic transplantation: durable cyto-
genetic remission and conversion to complete donor chimerism
without GVHD. Blood 2003;102:462b(abstr.)
. Morris EC, Rebello P, Thomson KJ, et al. Pharmacokinetics
of alemtuzumab used for in vivo and in vitro T-cell depletion
in allogeneic transplantations: relevance of early adoptive im-
munotherapy and infectious complications. Blood 2003;102:
404-406.
. Hallemeier, MD
one Marrow Transplantation & Leukemia
ashington University School of Medicine
t. Louis, Missouri
727
